A Review of Recent Advances in the Therapeutic Uses of Secondary Cannabinoids

Current Addiction Reports

Volumn 3, Issue 2, 2016, Pages 230-238

  Morabito, Danielle ^a   Soyster, Peter ^b   Ramey Wright, Shaw ^a,c   Belendiuk, Katherine A ^a,d   Bonn Miller, Marcel O ^a,d,e  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cannabinoids; Cannabis; CBD; Marijuana; THC

Indexed keywords

EID: 85014716856     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-016-0096-9     Document Type: Review

References (83)

1. Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10(1):10.
2. ProCon.org (US). Number of legal medical marijuana patients [Internet]. Santa Monica (CA): ProCon.org. 2015 [cited 2016 Jan 20]. Available from: http://medicalmarijuana.procon.org/view.resource.php?resourceID=005889.
3. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474–83.
4. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.
5. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–48.
6. Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in cannabis (cannabaceae). Am J Bot. 2004;91(6):966–75.
7. Walter C, Oertel B, Lötsch J. THC may reproducibly induce electrical hyperalgesia in healthy volunteers. Eur J Pain. 2015;19(4):516–8.
8. Notcutt WG. Clinical use of cannabinoids for symptom control in multiple sclerosis. Neurotherapeutics. 2015;12(4):769–77.
9. Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in maritime Canada. Can J Infect Dis Med Microbiol. 2014;25(1):e1.
10. Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. 2015;97(6):575–86.
11. Almeida V, Levin R, Peres FF, Niigaki ST, Calzavara MB, Zuardi AW, et al. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;41:30–5.
12. Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–26.
13. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–74.
14. Campos AC, Ferreira FR, Guimaraes FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. 2012;46(11):1501–10.
15. Campos AC, de Paula SV, Carvalho MC, Ferreira FR, Vicente MA, Brandão ML, et al. Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology. 2013;226(1):13–24.
16. Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Diaz-Alonso J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. 2013;16(6):1407–19.
17. Chagas M, Eckeli A, Zuardi A, Pena‐Pereira M, Sobreira‐Neto M, Sobreira E, et al. Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–6.
18. Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121–30.
19. Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology. 2013;226(4):781–92. Randomized controlled trial that found CBD to help extinction learning in a fear conditioning paradigm. This indicated the potential benefit of CBD in conjunction with extinction therapies for anxiety disorders.
20. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology. 2012;219(3):859–73.
21. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2015. doi:10.1016/S1474-4422(15)00379-8. Provides support for the use of isolated cannabidiol as an anticonvulsant in addition to existing anti-epileptic drug treatment regimens in treatment-resistant pediatric epilepsy.
22. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.
23. Fogaça M, Reis F, Campos A, Guimarães F. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT 1A receptors and previous stressful experience. Eur Neuropsychopharmacol. 2014;24(3):410–9. Animal study that implicates 5HT1A receptors as a mechanism of treatment efficacy, and previous stressful experience as a moderator for the anxiolytic effects of CBD.
24. Gomes FV, Resstel LB, Guimarães FS. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology. 2011;213(2–3):465–73.
25. Granjeiro EM, Gomes FV, Guimaraes FS, Corrêa FM, Resstel LB. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav. 2011;99(4):743–8.
26. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344–52.
27. Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94.
28. Liput DJ, Hammell DC, Stinchcomb AL, Nixon K. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Behav. 2013;111:120–7.
29. 9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol. 2010;13(7):861–76.
30. Marinho A, Vila-Verde C, Fogaça M, Guimarães F. Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT 1A receptors and stressful experiences. Behav Brain Res. 2015;286:49–56.
31. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7. Provides support for the use of cannabidiol as an anticonvulsant in pediatric epilepsy.
32. Reus GZ, Stringari RB, Ribeiro KF, Luft T, Abelaira HM, Fries GR, et al. Administration of cannabidiol and imipramine induces antidepressant‐like effects in the forced swimming test and increases brain‐derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatrica. 2011;23(5):241–8.
33. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel‐induced neuropathic pain through 5‐HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014;171(3):636–45.
34. Zanelati T, Biojone C, Moreira F, Guimaraes F, Joca S. Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1A receptors. Br J Pharmacol. 2010;159(1):122–8.
35. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. Double-blind, randomized clinical trial of 51 cannabis dependent treatment-seeking individuals. After nabiximol administration, individuals reported reduced cannabis withdrawal symptoms and patient retention improved relative to placebo. This shows the potential of nabiximols as a treatment for cannabis use disorder.
36. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–9.
37. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71(5–6):271–9.
38. Hoggart B, Ratcliffe S, Ehler E, Simpson K, Hovorka J, Lejčko J, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262(1):27–40. Shows decreased pain and improved sleep quality in a large sample (n = 380) of individuals with neuropathic pain over the course of 38 weeks. Provides evidence for the safety of prolonged nabiximol use.
39. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167–79.
40. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46(2):207–18.
41. Langford R, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–97. doi:10.1007/s00415-012-6739-4.
42. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex®(nabiximols). Mult Scler J. 2012;18(2):219–28.
43. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–31.
44. Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.
45. Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260(1):285–95. Clinical trial of repeated Sativex use up to 48 doses per day with no psychoses, adverse event trends, or withdrawal symptoms observed. Demonstrates that Sativex is well tolerated, and can provide sustained reduction in MS spasticity symptoms.
46. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130(1):216–21.
47. Zuardi A, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2008;23:979–83.
48. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485–6.
49. Johnson L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the future national survey results on drug use: 1975–2013: overview. Key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2014.
50. Cunha JM, Carlini E, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175–85.
51. Mechoulam R, Carlini E. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65(4):174–9.
52. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. International Conference on Cannabis and Cannabinoids. Kolympari, Crete; 1990.
53. Jones N, Hill A, Hill T, Peres I, Hadid R, Wright S, et al. Assessment of the anticonvulsant effects and tolerability profile of cannabidiol: GW pharmaceuticals’ preclinical program (P4. 255). Neurology. 2015;84(14 Supplement):P4. 255. Demonstrates promising anticonvulsant effects of CBD in vitro and in vivo with a favorable tolerability profile, providing support for future clinical investigation.
54. Gedde M, Maa E. Whole cannabis extract of high concentration cannabidiol may calm seizures in highly refractory pediatric epilepsies. American Epilepsy Society, 67th annual meeting. 2013.
55. Ames F, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1986;69(1):14.
56. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther. 2001;1(3–4):103–32.
57. Feliú A, Moreno‐Martet M, Mecha M, Carrillo‐Salinas F, Lago E, Fernández‐Ruiz J, et al. A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis. Br J Pharmacol. 2015;172:3579–95.
58. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012;3(5):400–6.
59. Sativex oromucosal spray—summary of product characteristics (SPC) - (eMC).
60. Fernández O. Advances in the management of MS spasticity: recent observational studies. Eur Neurol. 2014;72 Suppl 1:12–4.
61. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82(17):1556–63.
62. Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung H-P, Kieseier BC. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord. 2012;5(5):255–66.
63. Rekand T. THC: CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol. 2014;71 Suppl 1:4–9.
64. Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014;74(5):563–78.
65. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707–14.
66. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain®. 2007;133(1):210–20.
67. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta‐analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–84.
68. Hill A, Mercier M, Hill T, Glyn S, Jones N, Yamasaki Y, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167(8):1629–42.
69. Hill T, Cascio MG, Romano B, Duncan M, Pertwee R, Williams C, et al. Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism. Br J Pharmacol. 2013;170(3):679–92.
70. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306–16.
71. Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, et al. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol. 2013;169(1):213–29.
72. Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J NeuroImmune Pharmacol. 2012;7(4):1002–16.
73. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014. doi:10.1093/carcin/bgu205.
74. Wargent E, Zaibi M, Silvestri C, Hislop D, Stocker C, Stott C, et al. The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3(5):e68.
75. Garcia C, Palomo‐Garo C, García‐Arencibia M, Ramos J, Pertwee R, Fernández‐Ruiz J. Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson’s disease. Br J Pharmacol. 2011;163(7):1495–506.
76. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.
77. Andréasson S, Engström A, Allebeck P, Rydberg U. Cannabis and schizophrenia a longitudinal study of Swedish conscripts. Lancet. 1987;330(8574):1483–6.
78. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3.
79. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012;72(10):811–6.
80. Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev. 2015. doi:10.1111/dar.12323.
81. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduction J. 2009;6(1):35. doi:10.1186/1477-7517-6-35.
82. Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, et al. An improved brief measure of cannabis misuse: the cannabis use disorders identification test—revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1):137–43.
83. Bujarski S, Galang JN, Short NA, Trafton JA, Gifford E, Kimerling R, et al. Cannabis use disorder treatment barriers/facilitators among veterans with PTSD. Psychol Addict Behav. 2016;30:73–81.